Jounce Therapeutics to Present at AACR Annual Meeting on JTX-2011 Cancer Immunotherapy Program
March 22 2017 - 4:01PM
-- Invited oral presentation on JTX-2011
preclinical data --
Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company
focused on the discovery and development of novel cancer
immunotherapies coupled with predictive biomarkers for patient
enrichment, today announced it has been invited to present
preclinical data that support the ongoing Phase 1/2 ICONIC trial of
JTX-2011, an agonist monoclonal antibody targeting ICOS (Inducible
T cell CO-Stimulator), during an oral session at the American
Association for Cancer Research (AACR) Annual Meeting 2017 taking
place April 1-5, 2017 in Washington, D.C. In addition, there
will be a poster presentation covering the ICONIC trial design,
objectives, and eligibility criteria.
Details on the presentations include:
Oral PresentationPreclinical assessment of
JTX-2011, an agonist antibody targeting ICOS, supports evaluation
in ICONIC clinical trialSession SY19: Emerging Targets in
ImmunotherapyHall D,E, Level 2, Washington Convention Center1:35 -
2:00 p.m. ET, Sunday, April 2, 2017
Poster Presentation on Trial DesignICONIC:
Phase 1/2 Trial of ICOS Agonist JTX-2011 Alone and in Combination
with Nivolumab (nivo)Session POCT01: Phase 1 Clinical Trials in
ProgressSection 338:30 a.m. – 12 p.m. ET, Monday, April 3, 2017
The company remains on track to report safety and PK/PD data
from the Phase 1 portion of the ICONIC trial at a later date in the
first half of 2017 and preliminary efficacy data in the second half
of 2017.
About JTX-2011Jounce’s lead product candidate,
JTX-2011, is a monoclonal antibody that binds to and activates
ICOS, a protein on the surface of certain T cells.
Pre-clinical data supports that JTX-2011 may have a dual mechanism
of action that stimulates anti-tumor T effector cells, and also
reduces the immunosuppressive T regulatory cells in the tumor
microenvironment. The company is developing JTX-2011 to treat solid
tumors as a single agent and in combination with other
therapies.
About Jounce Therapeutics Jounce Therapeutics,
Inc. is a clinical stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long‑lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within tumors
to prioritize targets, and then identifies related biomarkers
designed to match the right therapy to the right patient. Jounce’s
lead product candidate, JTX-2011, is a monoclonal antibody that
binds to and activates ICOS and is currently in a Phase 1/2 trial.
For more information, please visit http://jouncetx.com/.
Forward-Looking StatementsVarious statements in
this release concerning Jounce’s future expectations, plans and
prospects, including without limitation, Jounce’s expectations
regarding the timing, progress and results of preclinical studies
and clinical trials for Jounce’s product candidates and any future
product candidates; the timing, scope or likelihood of regulatory
filings and approvals; and Jounce’s ability to identify new targets
for additional product candidates, to develop future product
candidates and combination therapies, and to successfully
commercialize and market products may constitute forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995 and other federal
securities laws and are subject to substantial risks, uncertainties
and assumptions. You should not place reliance on these forward
looking statements, which often include words such as “anticipate,”
“estimate,” “expect,” “intend,” “may,” “on track,” “plan,”
“predict,” “target,” “potential” or similar terms, variations of
such terms or the negative of those terms. Although the Company
believes that the expectations reflected in the forward-looking
statements are reasonable, the Company cannot guarantee such
outcomes. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, as well as those risks more fully discussed in
the section entitled “Risk Factors” in Jounce’s most recent annual
report on Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in Jounce’s subsequent
filings with the U.S. Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Media Contact:
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
Investor Contact:
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024